Search | Clinical Trials Finder

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: pembrolizumab/vibostolimab, durvalumab, cisplatin, pemetrexed, etoposide, carboplatin, paclitaxel, thoracic radiotherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Hollywood, Florida + 18 more

Conditions: Non-small Cell Lung Cancer
Interventions: Canakinumab, Durvalumab, Radiation therapy, Chemotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer
Interventions: lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis, microarray analysis, immunohistochemistry staining method, biopsy, radiation therapy; Drug · Genetic · Other + 2 more
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Radiotherapy, Radiotherapy, Image-Guided
Interventions: Patient Position Monitoring System; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lung Cancer, Metastatic Cancer
Interventions: Treatment Planning using the DIBH Technique; Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Thoracic Neoplasms, Lumbar Neoplasm
Interventions: kyphoplasty with Osteocool; Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Thoracic Radiotherapy, Durvalumab; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 33
States / cities: Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more

Conditions: Phenylketonuria
Interventions: Preparative Radiation Therapy, Hepatocyte Transplant, Immunosuppression, Liver Evaluation, Neuro-psychological Assessment, Whole body Phe oxidation testing, Liver Biopsy; Radiation · Procedure · Drug + 3 more
Lead sponsor: Ira Fox; Other
Eligibility: 14 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Esophagitis
Interventions: Whole Food Intervention; Dietary Supplement
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Colorectal Cancer, Head and Neck Cancer
Interventions: Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid); Drug · Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Soft Tissue Sarcoma
Interventions: Hypofractionated Radiation Therapy; Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions: Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy; Radiation · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 56
States / cities: Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more

Conditions: Lung Cancer
Interventions: Bronchoscopic Implantation, Cone-Beam CT-Guided, stereotactic body radiation treatments; Procedure · Device · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 3
States / cities: Commack, New York • Harrison, New York • New York, New York

Conditions: Invasive Breast Cancer, Post-mastectomy
Interventions: Radiotherapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 30 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Toxicity
Interventions: Complementary and alternative medicine (CAM); Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lung Cancer
Interventions: monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody GD2 anti-idiotype vaccine, cisplatin, etoposide, radiation therapy; Biological · Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 99
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
Interventions: Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 1,656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 154
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more

Conditions: Limited-Stage Small Cell Lung Cancer
Interventions: HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI); Drug · Radiation
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 31
States / cities: Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more

Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy; Drug · Radiation
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Gilbert, Arizona • Tucson, Arizona • Seattle, Washington

Conditions: Radiation Injury, Breast Cancer
Interventions: Proton beam radiation therapy., X-ray based radiation therapy, Computed Tomography (CT) Scan, Pulmonary Function Test (PFT); Radiation · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Advanced Solid Tumors
Interventions: M3814 100 mg, M3814 200 mg, M3814 300 mg, M3814 400 mg, M3814 50 mg, Fractionated RT, Cisplatin; Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 9
States / cities: Fresno, California • Fort Lauderdale, Florida • Miami, Florida + 6 more

Conditions: Breast Cancer
Interventions: therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy; Biological · Drug · Genetic + 3 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Tampa, Florida • Omaha, Nebraska

Conditions: Pancreatic Cancer
Interventions: CyberKnife based stereotactic radiotherapy, Gemcitabine, Fludeoxyglucose (18F) (FDG); Device · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Stanford, California • Baltimore, Maryland • New York, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Tremelimumab, Thoracic Radiation, lobectomy, Standard of care adjuvant chemotherapy; Drug · Radiation · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

Patient Position Monitoring System for Beam Gated Radiation Therapy of Malignancies of the Chest and Upper Abdomen

Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Close Proximity to the Chest Wall

Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Liver Cell Transplant for Phenylketonuria

The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies

Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer

Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences

S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Breast Cancer Lung Late Effects

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer